An Escherichia coli-based bioengineering strategy to study streptolysin S biosynthesis.

Group A Streptococcus pyogenes (GAS) is a leading human pathogen that produces a powerful cytolytic bacteriocin known as streptolysin S (SLS). We have developed a bioengineering strategy to successfully reconstitute SLS activity using heterologous expression in laboratory strains of Escherichia coli. Our E. coli-based heterologous expression system will allow more detailed studies into the biosynthesis of other bacteriocin compounds and the production of these natural products in much greater yield.